Latest News on IRTC

Financial News Based On Company


Advertisement
Advertisement

Why iRhythm stock is trading up today

https://www.tradingview.com/news/stockstory:e456b68d4094b:0-why-irhythm-stock-is-trading-up-today/
Shares of iRhythm Technologies (IRTC) rose 4.2% after the company's board authorized a $200 million share repurchase program on November 10, 2026. This buyback is supported by the company's strong core business and prospects from VitalConnect. The market views this news as meaningful, although iRhythm's shares have been volatile, and the stock is down significantly year-to-date.

iRhythm Technologies, Inc. (IRTC) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/IRTC/
This article provides a comprehensive overview of iRhythm Technologies, Inc. (IRTC) stock, including its current price, key statistics, historical data, and company profile. It details the company's offerings in ambulatory cardiac monitoring services and highlights recent financial performance, analyst ratings, and valuation measures. The report also includes comparisons of IRTC's trailing total returns against the S&P 500 benchmark.

IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)

https://www.morningstar.com/news/pr-newswire/20261106ny91572/irtc-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-irhythm-technologies-inc-irtc
SueWallSt is investigating iRhythm Technologies, Inc. (NASDAQ: IRTC) for potential securities law violations after the company reported third-quarter revenue below consensus, flat Zio AT sales, and delayed the Zio MCT FDA submission to 2027. IRTC shares fell significantly following the announcement. Investors who incurred losses are encouraged to contact SueWallSt for a free review of their potential recovery options.

iRhythm plunges after Q3 miss, Zio MCT delay (IRTC:NASDAQ)

https://seekingalpha.com/news/4668393-irhythm-stock-down-q3-miss-zio-mct-delay
Shares of iRhythm Technologies (IRTC) hit a new 52-week low after reporting weaker-than-expected Q3 2026 results. The cardiac device maker also announced a delayed timeline for submitting FDA filings for its upcoming mobile cardiac device, Zio MCT. This news contributed to the significant drop in the company's stock price.

Needham cuts iRhythm stock price target on Zio AT weakness By Investing.com

https://ca.investing.com/news/stock-market-news/needham-cuts-irhythm-stock-price-target-on-zio-at-weakness-93CH-4938298
Needham has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) shares from $194 to $165, while maintaining a Buy rating, citing weakness in the company's Zio AT product due to purchasing delays. Despite the Zio AT softness, iRhythm still anticipates achieving $1 billion in organic revenue in 2027 and meeting its long-range plan margin targets. The company's third-quarter 2026 revenue met expectations, but the updated 2026 revenue guidance implies lower underlying iRhythm revenue, though this is offset by VitalConnect's contribution.
Advertisement

What iRhythm Technologies (IRTC) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:a3f08722f094b:0-what-irhythm-technologies-irtc-said-on-its-q3-earnings-call/
iRhythm Technologies (IRTC) raised its 2026 revenue and profitability outlook after strong third-quarter growth, primarily driven by its Zio monitor business, despite softer demand for its Zio AT product. The company also announced a delay in the submission of its next-generation Zio MCT product to the FDA until 2027, prioritizing the integration of its recent VitalConnect acquisition. iRhythm reported significant improvements in gross margin and adjusted EBITDA, with a positive adjusted net income, while its GAAP net loss included a $50 million litigation settlement charge.

How a deal is helping a remote monitoring company enter hospitals

https://www.modernhealthcare.com/medical-devices/mh-irhythm-quentin-blackford-ai-cardiac-care/
iRhythm Technologies is expanding its reach into hospitals through a new deal. The article focuses on how this agreement will allow the remote monitoring company to integrate its Zio monitor into hospital settings, marking a significant step for cardiac care technology within traditional healthcare environments. The move reflects a trend towards greater integration of remote patient monitoring solutions in mainstream medical practice.

iRhythm Technologies Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62959118/irhythm-technologies-q3-2026-earnings-call-transcript
iRhythm Technologies reported strong Q3 2026 results with revenue up nearly 15% year-over-year to $221.6 million, driven by its Zio Monitor business and achieving record gross and adjusted EBITDA margins. The company completed the acquisition of VitalConnect, expanding its cardiac monitoring capabilities and market opportunity, and raised its full-year 2026 revenue guidance to $890-895 million. While prioritizing VitalConnect's integration and commercialization, iRhythm also announced a delay in its next-generation Zio MCT program submission to the FDA until 2027, attributing Zio AT's flat performance to customer purchasing delays related to the VitalConnect acquisition.

Earnings to watch: iRhythm (IRTC) reports Q3 results tomorrow

https://www.tradingview.com/news/stockstory:86fabb918094b:0-earnings-to-watch-irhythm-irtc-reports-q3-results-tomorrow/
iRhythm Technologies (IRTC) is set to announce its Q3 earnings results, with analysts expecting a 15.3% year-on-year revenue growth. The company has a history of exceeding Wall Street's expectations and reported strong Q2 results, beating revenue and EPS estimates. Positive sentiment is noted in the healthcare equipment and supplies segment, with iRhythm's shares up 15.8% over the last month.

iRhythm Technologies Inc (I25.MU) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/I25.MU/seasonality/
The article provides a seasonal returns chart for iRhythm Technologies Inc (I25.MU), showing average monthly price returns from 2021 to 2026. It also notes the company's stock performance on the Munich exchange and the upcoming Q3 2026 earnings call.
Advertisement

Precision Trading with Irhythm Technologies Inc. (IRTC) Risk Zones

https://news.stocktradersdaily.com/news_release/15/Precision_Trading_with_Irhythm_Technologies_Inc._IRTC_Risk_Zones_110226013201_1793601121.html
This article provides an in-depth analysis of Irhythm Technologies Inc. (IRTC) using AI-generated signals for precision trading. It outlines key findings regarding sentiment and price positioning, offering distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles. The analysis includes support and resistance levels across near-term, mid-term, and long-term horizons to guide trading decisions.

iRhythm Says Data Breach Affected 8.2 Million People

https://the420.in/irhythm-says-data-breach-affected-8-2-million-people/
Cardiac-monitoring company iRhythm Technologies disclosed a data breach that affected 8.2 million people after attackers accessed third-party-hosted business applications. The breach exposed personal, insurance, and device-related information, including names, addresses, dates of birth, and insurance numbers, though clinical and device systems were not affected. iRhythm detected the unauthorized access between June 3 and June 8, 2026, and later faced an extortion attempt.

Piper Sandler sets USD 160.00 target for iRhythm stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/piper-sandler-sets-usd-160-00-target-for-irhythm-stock/70378236
Piper Sandler has initiated coverage of iRhythm Technologies (IRMD) with an Overweight rating and a price target of USD 160.00, set on October 16, 2026. This target represents a significant premium over the stock's current Nasdaq price. The company reported strong Q2 2026 results with a 20.1% increase in revenue and a shift from an adjusted net loss to a profit.

Quentin Blackford, iRhythm Technologies

https://www.investmentreports.co/interview/quentin-blackford-2704
Quentin Blackford, President & CEO of iRhythm Technologies, discusses the company's shift from reactive to proactive and predictive cardiac monitoring, leveraging AI and vast patient data. He highlights the expansion of monitoring capabilities through the VitalConnect acquisition and the potential for earlier arrhythmia detection in patients with co-morbidities like diabetes and kidney disease. Blackford emphasizes the economic benefits of proactive monitoring in reducing healthcare costs and improving patient outcomes, with a future focus on population health and sleep disorder diagnosis.

Piper Sandler sets USD 160.00 target for iRhythm Technologies stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/piper-sandler-sets-usd-160-00-target-for-irhythm-technologies-stock/70351695
Piper Sandler has set a price target of USD 160.00 for iRhythm Technologies (IRMD) stock, representing a significant premium over its recent Nasdaq price of USD 108.66. The company reported a 20.1 percent increase in second-quarter revenue to USD 224.17 million, with an improved gross margin and narrowed GAAP net loss. Investors are awaiting the third-quarter results scheduled for November 5, 2026, which will serve as a key checkpoint for the stock's valuation.
Advertisement

Piper Sandler Initiates IRhythm Technologies at Overweight With $160 Price Target

https://www.moomoo.com/news/post/1001442614/piper-sandler-initiates-irhythm-technologies-at-overweight-with-160-price
Piper Sandler has initiated coverage of iRhythm Technologies (IRTC) with an Overweight rating and a price target of $160. This new rating suggests a positive outlook on the company's stock by the investment bank.

Piper Sandler Initiates iRhythm Technologies at Overweight With $160 Price Target

https://finance.yahoo.com/markets/stocks/articles/piper-sandler-initiates-irhythm-technologies-115137800.html
Piper Sandler has initiated coverage on iRhythm Technologies (IRTC) with an "Overweight" rating and a price target of $160. The article notes that IRTC currently has an average analyst rating of "buy" and a mean price target of $171.33. The full details of the analysis are behind a premium paywall.

Piper Sandler initiates iRhythm stock with overweight rating

https://www.investing.com/news/analyst-ratings/piper-sandler-initiates-irhythm-stock-with-overweight-rating-93CH-4953429
Piper Sandler has initiated coverage on iRhythm Technologies (NASDAQ:IRTC) with an Overweight rating and a $160 price target, projecting significant growth despite the stock's year-to-date decline. The firm believes the market has already priced in concerns such as an FDA warning letter and a DOJ investigation, seeing substantial opportunity in the mobile cardiac telemetry market with upcoming product launches. This positive outlook follows iRhythm's strong Q2 2026 revenue and improved profitability, leading to raised revenue guidance for the year.

Needham lifts target for iRhythm Technologies stock to USD 194.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/needham-lifts-target-for-irhythm-technologies-stock-to-usd-194-00/70332371
Needham has increased its price target for iRhythm Technologies (IRTC) stock to $194.00 from $192.00, citing the company's strong second-quarter revenue of $224.17 million. Despite the stock trading at EUR 95.25 on October 15, 2026, the new target represents an 81.61 percent increase over its Nasdaq price. iRhythm is scheduled to report its third-quarter earnings on November 5, 2026, which will include updated 2026 financial guidance incorporating VitalConnect.

Piper Sandler Initiates IRhythm Technologies(IRTC.US) With Buy Rating, Announces Target Price $160

https://www.moomoo.com/news/post/1001426257/piper-sandler-initiates-irhythm-technologies-irtcus-with-buy-rating-announces
Piper Sandler has initiated coverage of iRhythm Technologies (IRTC.US) with a Buy rating. The firm has also set a target price of $160 for the company's stock, signaling a positive outlook for its future performance.
Advertisement

News - iRhythm said June data breach exposes data of over 360,000 people

https://www.teiss.co.uk/news/irhythm-said-june-data-breach-exposes-data-of-over-360000-people-18304
Medical device manufacturer iRhythm disclosed a data security incident from June 2026, affecting over 360,000 individuals. A threat actor exfiltrated sensitive personal information, including names, contact details, and patient identification numbers, after demanding payment to prevent public disclosure. The company states the incident has not impacted its products, clinical systems, or financial condition and is covered by cybersecurity insurance.

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

https://www.morningstar.com/news/pr-newswire/20261013ny71128/did-irhythm-technologies-inc-insiders-breach-their-fiduciary-duties-to-shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. The firm encourages current long-term shareholders to contact them to discuss potential corporate governance reforms, the return of funds to the company, or other legal relief. This investigation aims to enhance shareholder value through improved company policies, practices, and oversight.

(IRTC) as a Liquidity Pulse for Institutional Tactics

https://news.stocktradersdaily.com/news_release/35/IRTC_as_a_Liquidity_Pulse_for_Institutional_Tactics_101226041402_1791836042.html
This article provides an AI-driven analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), highlighting weak sentiment across all horizons and suggesting a short bias. It outlines three institutional trading strategies with specific entry, target, and stop-loss points for position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal analysis and risk-reward setups, emphasizing a notable 65.3:1 risk-reward ratio.

iRhythm Data Breach Impacts at Least 360,000 People

https://www.securityweek.com/irhythm-data-breach-impacts-over-360000-people/
Medical equipment provider iRhythm has reported a data breach affecting over 360,000 individuals, where hackers exfiltrated personal and account information from third-party hosted business applications. The company was contacted by the hackers seeking a ransom, but iRhythm states it has no evidence the stolen data has been used for identity theft. The breach did not impact iRhythm's products, clinical systems, or financial condition.

iRhythm data breach may affect 8.2 mn people, hackers stole patient information

https://beinsure.com/news/irhythm-data-breach-may-affect-8mn-people/
Medical technology provider iRhythm confirmed a data breach affecting approximately 8.18 million people nationwide, with hackers stealing patient information from third-party-hosted applications between June 3 and June 8, 2026. The compromised data includes names, addresses, emails, phone numbers, dates of birth, account numbers, device serial numbers, health insurance numbers, and dates of medical services. Although hackers demanded payment, iRhythm reports no impact on medical devices, patient safety, or clinical operations and maintains that the incident is unlikely to have a material financial effect, despite carrying cybersecurity insurance.
Advertisement

Hundreds of thousands impacted by data breach at biosensor firm iRhythm

https://therecord.media/irhythm-data-breach-reports
Medical device maker iRhythm disclosed a data breach in June 2026, impacting at least 360,000 individuals in Texas and South Carolina. Hackers gained access to third-party business applications through a social engineering attack, stealing personal and patient account information. The company stated that clinical systems and devices were not affected, and there is no evidence of identity theft.

iRhythm Holdings (IRTC) Disclosed Unauthorized Access To Patient Data

https://finance.yahoo.com/healthcare/articles/irhythm-holdings-irtc-disclosed-unauthorized-081242802.html
iRhythm Holdings (IRTC) has reported a cybersecurity incident involving unauthorized access to patient data, prompting a regulatory investigation and revised financial guidance. The company is working with law enforcement and cybersecurity experts to assess the impact and implement remediation steps. This incident highlights data privacy and regulatory risks for iRhythm, a digital healthcare provider specializing in ambulatory cardiac monitoring, and its implications for the company's operational and financial resilience will be closely watched in upcoming quarterly reports.

iRhythm Notifies Individuals Affected by June 2026 Hacking Incident

https://www.hipaajournal.com/irhythm-data-breach/
iRhythm, a health technology company specializing in wearable cardiac monitoring devices, has begun notifying individuals affected by a June 2026 hacking and data theft incident. The breach compromised patient names, addresses, phone numbers, email addresses, account numbers, device serial numbers, insurance numbers, dates of birth, and service dates for hundreds of thousands of individuals, including over 368,000 in Texas and South Carolina. While iRhythm reports no impact on its products or patient safety and is unaware of data misuse, the incident was deemed material due to the volume of data potentially stolen.

Wells Fargo Keeps Their Buy Rating on Irhythm Technologies (IRTC)

https://www.theglobeandmail.com/investing/markets/stocks/IRTC-Q/pressreleases/5001528/wells-fargo-keeps-their-buy-rating-on-irhythm-technologies-irtc/
Wells Fargo has maintained a Buy rating on Irhythm Technologies (IRTC) with a price target of $150.00, citing the company's financial performance and recent acquisition. Despite negative insider sentiment, analysts have a "Strong Buy" consensus for IRTC with a significant upside from current levels. Needham also reiterated a Buy rating with a higher price target.

Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH) and Irhythm Technologies (IRTC)

https://www.theglobeandmail.com/investing/markets/stocks/OPCH/pressreleases/5003123/analysts-offer-insights-on-healthcare-companies-option-care-health-opch-and-irhythm-technologies-irtc/
This article highlights bullish sentiments from analysts on two healthcare companies: Option Care Health (OPCH) and Irhythm Technologies (IRTC). Truist Financial maintained a Buy rating on Option Care Health with a price target indicating a 14.4% upside. Canaccord Genuity also maintained a Buy rating on Irhythm Technologies with a price target suggesting a 58.5% upside, leading to a "Strong Buy" consensus for IRTC.
Advertisement

iRhythm Technologies (IRTC): Cyberattack Disclosure Turns Data Risk Into an Investor Catalyst

https://news.alphastreet.com/irhythm-technologies-irtc-cyberattack-disclosure-turns-data-risk-into-an-investor-catalyst/amp/
iRhythm Technologies (IRTC) reported strong Q2 2026 results with revenue up 20.1% and improved margins, alongside raised full-year guidance, despite a cybersecurity incident disclosed in June. The company has now begun notifying impacted individuals, shifting the focus to potential costs from legal, regulatory, and reputational risks. Investors are watching whether core demand remains strong, if breach-related costs are manageable, and if trust in the company's data handling persists.

iRhythm completes acquisition of VitalConnect

https://www.massdevice.com/irhythm-completes-acquisition-of-vitalconnect/
iRhythm has finalized its $287.5 million acquisition of VitalConnect, a cardiac monitoring tech company. This deal aims to broaden iRhythm's offerings beyond wearable heart patches to a more comprehensive cardiac monitoring and intelligence platform. The acquisition is expected to enhance iRhythm's revenue growth while maintaining its adjusted EBITDA margin target of 15% for 2027.

iRhythm stock price target lowered to $150 by Wells Fargo on model update

https://www.investing.com/news/analyst-ratings/irhythm-stock-price-target-lowered-to-150-by-wells-fargo-on-model-update-93CH-4933912
Wells Fargo lowered its price target for iRhythm Technologies (NASDAQ:IRTC) stock to $150 from $168, while maintaining an Overweight rating, following the acquisition of VitalPatch. Despite the stock appearing overvalued by InvestingPro analysis, analysts maintain a bullish consensus. The firm updated its sales forecasts for 2026 and 2027, incorporating VitalPatch sales and anticipating some cannibalization of existing product lines, while also adjusting gross and EBITDA margin forecasts.

IRhythm: Transaction Expected to Enhance Rev Growth Rate Beginning in 2027 >IRTC

https://www.moomoo.com/news/post/1000607267/irhythm-transaction-expected-to-enhance-rev-growth-rate-beginning-in
This article discusses IRhythm (IRTC) and a transaction expected to improve its revenue growth rate starting in 2027.

A heart-monitoring platform can track up to 11 body signals. iRhythm bought VitalConnect.

https://www.stocktitan.net/news/IRTC/i-rhythm-completes-acquisition-of-vital-connect-expanding-its-ub0pzjc5p2ky.html
iRhythm Holdings has completed its acquisition of VitalConnect, expanding its cardiac monitoring platform with mobile cardiac telemetry and multi-vitals monitoring capabilities. The acquisition involved $237.5 million in cash and up to 423,334 shares, with an additional $10 million in working capital provided to VitalConnect. iRhythm expects this strategic move to enhance its revenue growth starting in 2027 while maintaining its 15% adjusted EBITDA margin target for the same year.
Advertisement

IRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

https://www.marketscreener.com/news/irhythm-completes-acquisition-of-vitalconnect-expanding-its-cardiac-monitoring-platform-across-ambu-ce785dd8d889f72d
iRhythm Holdings, Inc. (Nasdaq: IRTC) has announced the completion of its acquisition of Vital Connect, Inc., a leader in wearable biosensor technology and ambulatory cardiac monitoring. This acquisition broadens iRhythm's cardiac monitoring portfolio, advances its multi-vitals strategy, and expands its addressable market across the continuum of care, including inpatient and hospital-to-home settings. The transaction is expected to enhance iRhythm's revenue growth rate starting in 2027 while maintaining its 15% adjusted EBITDA margin target for the same year.

iRhythm Holdings Finalizes Acquisition of Vital Connect Through iRhythm Technologies

https://kalkinemedia.com/us/news/announcements/irhythm-holdings-finalizes-acquisition-of-vital-connect-through-irhythm-technologies
iRhythm Holdings, Inc. announced the successful completion of its acquisition of Vital Connect, Inc. through its wholly owned subsidiary, iRhythm Technologies, Inc. The acquisition was finalized on October 5, 2026, making Vital Connect an indirect wholly owned subsidiary of iRhythm Holdings. Financial details of the transaction were not disclosed in the Form 8-K filing.

Patient insurance numbers and birth dates were in data downloaded during iRhythm's cyber incident

https://www.stocktitan.net/news/IRTC/i-rhythm-provides-update-on-cybersecurity-incident-previously-dodjzvj3g25y.html
iRhythm Holdings (IRTC) has begun notifying individuals affected by a cybersecurity incident that occurred between June 3 and June 8, 2026. Unauthorized individuals accessed and downloaded patient data including names, contact details, account and insurance numbers, device serial numbers, service dates, and birth dates. The company states there is no evidence of financial account or payment card information being compromised and believes the incident is not likely to have a material financial impact.

Wells Fargo Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $168

https://www.moomoo.com/news/post/1000196025/wells-fargo-maintains-irhythm-technologies-irtcus-with-buy-rating-maintains
Wells Fargo has reiterated its Buy rating for iRhythm Technologies (IRTC.US) and maintained its target price at $168. This indicates the firm's continued confidence in the company's financial prospects and stock performance.

iRhythm Technologies stock reports 20.1 percent revenue growth

https://www.ad-hoc-news.de/boerse/news/nebenwerte/irhythm-technologies-stock-reports-20-1-percent-revenue-growth/70175207
iRhythm Technologies reported Q2 2026 revenue of $224.17 million, marking a 20.1% increase year-over-year and beating analyst estimates. The company achieved adjusted EPS of $0.58, significantly exceeding expectations. Additionally, the Hart-Scott-Rodino waiting period for the Vital Connect acquisition expired, with the deal expected to close in early October 2026.
Advertisement

iRhythm Holdings, Inc. (IRTC) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/IRTC/
This article provides a comprehensive overview of iRhythm Holdings, Inc. (IRTC) stock, including its current price, historical data, key statistics, and company profile. It details iRhythm's digital healthcare business, focusing on ambulatory cardiac monitoring services and devices like the Zio system, and offers recent performance metrics, earnings trends, and analyst insights. The stock experienced a slight pre-market decline after closing at $111.75, with a 1-year return of 36.31% and a market cap of $3.684 billion.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Reach Out

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1209934
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (NASDAQ:IRTC) regarding potential corporate wrongdoing. The firm encourages shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis for class actions.

Trading Systems Reacting to (IRTC) Volatility

https://news.stocktradersdaily.com/news_release/35/Trading_Systems_Reacting_to_IRTC_Volatility_091126052202_1789161722.html
Irhythm Technologies Inc. (NASDAQ: IRTC) is showing weak near-term sentiment, potentially signaling a resumption of long-term weakness. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss zones. A mid-channel oscillation pattern is identified, with an exceptional 65.0:1 risk-reward setup targeting an 18.9% gain versus 0.3% risk.

iRhythm at Wells Fargo 21st annual healthcare conference: vitalconnect deal expands reach

https://ng.investing.com/news/stock-market-news/irhythm-at-wells-fargo-21st-annual-healthcare-conference-vitalconnect-deal-expands-reach-93CH-2689558
iRhythm Technologies Inc. presented its growth strategy at the Wells Fargo 21st Annual Healthcare Conference, focusing on the VitalConnect acquisition, new product launches, and commercial expansion. The company aims to broaden its access to the mobile cardiac telemetry market, despite anticipating slower revenue growth in the second half of 2026 due to tougher comparisons and pricing benefits not repeating. Management expressed confidence in achieving 30-40% market share in the mobile cardiac telemetry segment over time and reiterated its goal of exceeding $1 billion in revenue by 2027.

iRhythm To Buy VitalConnect, Plugging 30-Day MCT Gap And Broadening Its Cardiac Monitoring Platform

https://insights.citeline.com/medtech-insight/device-area/diagnostics/diagnostic-imaging/irhythm-to-buy-vitalconnect-plugging-30-day-mct-gap-and-broadening-its-cardiac-monitoring-platform-ZEOCLZQ64JCV3E3ANAJGZXXEHA/
iRhythm Technologies is set to acquire VitalConnect, a move that will expand iRhythm's cardiac monitoring platform. This acquisition is significant as it will allow iRhythm to cover the 30-day mobile cardiac telemetry (MCT) gap, enhancing its existing range of cardiac monitoring solutions. The integration of VitalConnect's technology is expected to broaden iRhythm's capabilities in the cardiac monitoring market.
Advertisement

Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-irhythm-tech-1209929
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) concerning corporate wrongdoing. The firm encourages investors who purchased iRhythm securities before January 11, 2022, and still hold them, to assist in the investigation. The firm operates on a contingency fee basis, only seeking reimbursement if successful in recovering funds for investors.

IRMD stock trades steadily as iRhythm Technologies posts strong Q2 2026 growth

https://www.ad-hoc-news.de/boerse/news/nebenwerte/irmd-stock-trades-steadily-as-irhythm-technologies-posts-strong-q2-2026/70058218
iRhythm Technologies (IRMD) stock is trading steadily around $123.07 in early September 2026, driven by strong Q2 2026 financial results. The company reported a significant revenue increase of 37.3% year-over-year to $563.0 million and improved adjusted gross margins, indicating robust growth in its digital cardiac monitoring business. Analyst sentiment remains positive, reflecting expectations for continued growth and profitability in the health technology sector.

iRhythm Technologies Inc. (IRTC) Key Financial Ratios – Valuation, Profitability & More

https://www.valueresearchonline.com/stocks/292753/irhythm-technologies-inc-irtc/key-ratios/
This article provides a detailed analysis of iRhythm Technologies Inc. (IRTC) key financial ratios, covering valuation, profitability, growth, solvency, and operating efficiency. It presents comparative data against peer medians for various metrics like Return on Equity, Net Margin, Revenue Growth, and Debt to Equity. The report highlights IRTC's performance in different financial areas up to TTM (Trailing Twelve Months) and annual periods.

Mobile ECG Devices Market Outlook 2025-2035 Featuring Profiles AliveCor, Apple and iRhythm Technologies - Industry Forecast to Reach $9.03 Billion by 2035 as Remote Cardiac Monitoring Adoption Accelerates

https://finance.yahoo.com/healthcare/articles/mobile-ecg-devices-market-outlook-114800368.html
The global mobile ECG devices market is projected to reach $9.03 billion by 2035, driven by increased adoption of remote cardiac monitoring and digital health solutions. The market, which was valued at $3.16 billion in 2025, is experiencing strong growth due to factors like the rising prevalence of cardiovascular diseases, an aging population, and the expansion of telemedicine. Key trends include AI-enabled wearables and point-of-care ECG solutions, with North America leading regional revenue and Asia-Pacific showing the fastest growth.

Mobile ECG Devices Market Outlook 2025-2035 Featuring

https://www.globenewswire.com/news-release/2026/09/02/3355044/0/en/mobile-ecg-devices-market-outlook-2025-2035-featuring-profiles-alivecor-apple-and-irhythm-technologies-industry-forecast-to-reach-9-03-billion-by-2035-as-remote-cardiac-monitoring-.html
The global mobile ECG devices market is projected to reach $9.03 billion by 2035, driven by the increasing adoption of remote cardiac monitoring, wearable technologies, and digital health solutions. Opportunities are emerging from AI-enabled wearable ECG bands, remote monitoring, point-of-care diagnostics, and home use, supported by telemedicine and preventive care, especially in emerging markets. North America was the largest regional market in 2025, while Asia-Pacific and the Middle East are expected to show the fastest growth.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement